Qiagen N.V. · NYSE:QGEN
Qiagen — Investor Presentation (2023)
24 slides from Qiagen's investor presentation, 2023
Slide 1: Making improvements in life possible
Making improvements in life possible QIAGEN Corporate Presentation 2023 Sample to Insight
Slide 2: Disclaimer
Disclaimer Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended
Slide 3: We help advance science and improve outcomes
We help advance science and improve outcomes Our Mission Enabling access to valuable insights from molecular research to clinical healthcare Our Vision Making improvements in life possible 3
Slide 4: Helping customers to make advances in science and patient care
Helping customers to make advances in science and patient care QIAGEN enters QIAGEN the molecular QIAGEN pioneers the diagnostic market launches the first plasmid with the first liquid prep kit, acquisition of biopsy-based cutting Digene and companion First QIAGEN instrument QIAGEN enters extraction
Slide 5: QIAGEN at a glance
QIAGEN at a glance A global company with scale ~45% $2.1 Americas billion Sales ~35% (2022 (2022) EMEA sales) ~20% Asia-Pacific / Japan Highly recurring revenues Balanced customer markets ~6,200 employees known as QIAGENers ~ 88% 12% ~ ~ 50% 50% ~ Consumables and related revenues Instruments Molecul
Slide 6: There is an unprecedented need for molecular research and testing
There is an unprecedented need for molecular research and testing to tackle the health challenges of our time Our knowledge about Tuberculosis is still Cancer remains a Infectious diseases the building blocks of one of the world’s leading cause of have been – and life – DNA, RNA and most significant
Slide 7: Researchers rely on QIAGEN to advance scientific discovery
Researchers rely on QIAGEN to advance scientific discovery Targeting metabolism is an important way of sensitizing tumors and making them more responsive to chemotherapy… and it’s not restricted to one particular type of cancer. Asha Palat, Doctoral Student at the university of Houston, Texas 7
Slide 8: Physicians rely on QIAGEN to improve clinical outcomes
Physicians rely on QIAGEN to improve clinical outcomes As long as we don’t have an answer about the respiratory virus status, we can’t admit a patient for hospitalization. Dr. Benoit Visseaux, Bichat-Claude Bernard Hospital, Paris 8
Slide 9: 500,000 customers
We help over 500,000 customers unlock molecular insights that address healthcare challenges. That’s how we help make improvements in life possible. 9
Slide 10: We are known for the highest quality products
We are known for the highest quality products 10
Slide 11: Our products are found in laboratories worldwide
Our products are found in laboratories worldwide - from young scientists to Nobel laureates 11
Slide 12: Our Sample technologies are the foundation of QIAGEN
Our Sample technologies are the foundation of QIAGEN A portfolio that has grown to address the complete spectrum of processing biological samples Selected biological samples Applications Tissue Stool Input demands Processing Target analytes Cloning qPCR / dPCR Cells Saliva Low / high-volume Manual G
Slide 13: QIAGEN provides solutions to uncover molecular insights from Sample to Insight
QIAGEN provides solutions to uncover molecular insights – faster, better and more efficiently – from Sample to Insight Biological Sample to Valuable sample Insight solutions molecular insights • Sample Technologies • Advancing knowledge about the building • Assay Technologies blocks of life – DNA, R
Slide 14: What does Sample to Insight look like in the Life Sciences?
What does Sample to Insight look like in the Life Sciences? Wastewater samples are collected and QIAGEN’s QIAcuity digital PCR system is QIAGEN bioinformatics are used to brought to a lab, where RNA and DNA are used to analyze target sequences analyze the data to monitor for new extracted with QIAGE
Slide 15: What does Sample to Insight look like in Molecular Diagnostics?
What does Sample to Insight look like in Molecular Diagnostics? A patient blood sample is collected using QIAGEN’s QuantiFERON-TB Gold Test results are delivered with one QIAGEN’s proprietary blood collection tubes Plus assay is used to analyze for latent visit and in less than 24 hours infections w
Slide 16: Life sciences: Working to enable scientific advancements
Life sciences: Working to enable scientific advancements QIAGEN value 2022 sales of ~$1 billion Recognized innovator supporting scientific breakthroughs Able to translate innovations into ~$5 billion commercial products addressable market Selected QIAGEN products Sample technologies Assay technologi
Slide 17: Molecular Diagnostics: Helping to improve outcomes in healthcare
Molecular Diagnostics: Helping to improve outcomes in healthcare QIAGEN value 2022 sales of ~$1.2 billion Focused on high-growth, high-demand opportunities Strong automation portfolio with multi-year ~$6 billion assay menu expansion underway addressable market Selected QIAGEN products Sample technol
Slide 18: Our Strategy: Leveraging a strong core portfolio to drive Pillars of Growth
Our Strategy: Leveraging a strong core portfolio to drive Pillars of Growth Expanding on solid leadership Early commercialization phases with strong growth potential Sample QuantiFERON QIAstat-Dx NeuMoDx QIAcuity technologies Leading immune Syndromic testing with Differentiated microfluidic Novel mi
Slide 19: We are ready to serve public health needs across the globe
And we are ready to serve public health needs across the globe Determined to leave no country behind with a portfolio of dedicated tests and strategic partnerships TB testing for low-resource Testing for high-risk human Sample technologies high-burden regions papillomavirus (HPV) using supporting de
Slide 20: Committed to building a sustainable business
Committed to building a sustainable business We have set ambitious goals to contribute to a more sustainable future – never compromising on our high quality standards By 2050: Goal: 36% 100% Carbon neutral women in leadership Strategic suppliers SBTI approved: 2030 interim in 2023 committed to goal:
Slide 21: Over 6,200 passionate QIAGENers around the world
>6,200 People from all functions working together to passionate QIAGENers achieve our vision: around the world are Making improvements employed by QIAGEN in life possible 21
Slide 22: We have a culture of empowerment driven by achieving targets
We have a culture of empowerment driven by achieving targets Decentralized decision-making • Giving teams at all levels greater influence • Bringing decisions closer to customers Ambitious but realistic targets • Appropriately balance opportunity and risk • Training teams on PREmortem analysis A cul
Slide 23: Our strong global presence serves both developed and emerging markets
Our strong global presence serves both developed and emerging markets >30 Our global Direct sales in and regional headquarters: Venlo Netherlands Germantown Global HQ countries Maryland Americas HQ Hilden Germany EMEA HQ Shanghai China HQ Singapore >170 Shipping product to Asia-Pacific HQ countries
Slide 24: QIAGEN is well positioned to support our customers
QIAGEN is well positioned to support our customers with their rapidly evolving scientific and testing needs. 24